org-25935
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2006 (NCT00700076)
Timeline
Indications
Mechanism of action
- Glycine transporter 1INHIBITOR
SLC6A9 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc2c(c1)CC[C@H](CN(C)CC(=O)O)[C@@H]2c1ccccc1- Mol. weight
- 339.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4228124 ↗
Also known as
- cis-n-methyl-n-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid hydrochloride
- n-methyl-n-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid
- org25935
- org 25935
- org 25935
- org 25935
- org-25935
- org-25935
- sch 900435
- sch 900435
- sch 900435
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00988728 | Phase 2 | Feb 1, 2011 | Merck |
| NCT00764660 | Phase 2 | Feb 1, 2009 | Merck |
| NCT00725725 | Phase 2 | Jul 1, 2008 | Merck |
| NCT00700076 | Phase 1 | Dec 1, 2006 | Organon, Yale University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 3 | 3 | 1 | 2008 |
| Organon | For profit | 1 | 0 | 1 | 2006 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2006 |
3 organizations
Page 1 / 1